Home / Precision Medicine

Precision Medicine

Concerto HealthAI Enters Precision Oncology Collaboration with Pfizer

Concerto HealthAI announced today that they have entered into a collaboration with Pfizer to advance work in Precision Oncology using Concerto HealthAI’s eurekaHealthTM platform, artificial intelligence (AI) models and Real World Clinical Electronic Medical Record (EMR) and healthcare claims. Data from clinical practices participating in the American Society of Clinical Oncology’s CancerLinQ® initiative …

Read More »

Foundation Medicine and Flatiron Publish Validation of Clinico-Genomic Database as a Platform to Advance Oncology Drug Development and Personalized Cancer Care

CAMBRIDGE, Mass. & NEW YORK–(BUSINESS WIRE)–Foundation Medicine and Flatiron Health today announced the publication of study results in the Journal of the American Medical Association validating that real-world clinico-genomic data obtained during the course of routine patient care can yield scientifically and clinically meaningful insights. These insights can serve as real-world evidence …

Read More »

Dystrogen Therapeutics Announces That Gene Therapy Successfully Cuts Off Production of Neuron-Destroying Protein in Huntington’s Disease

CHICAGO, April 5, 2019 /PRNewswire/ — Scientist from Dystrogen Therapeutics Corp. will present data supporting a potential cutting-edge therapy for neurodegenerative diseases caused by trinucleotide repeats, such as Huntington’s disease (HD) and spinocerebellar ataxias (SCAs). Early data confirmed that the therapy has the ability to selectively silence only the mutated …

Read More »

Researchers Find Genomic Testing Associated with Significantly Lower Health Care Costs in High-Risk Breast Cancer Patients

PLYMOUTH MEETING, Pa., March 19, 2019 /PRNewswire/ — New research from Duke University, published in the March 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network, provides evidence that genomic recurrence score (RS) testing using the 21-gene assay is associated with decreased cancer care costs in real-world practice among …

Read More »

Statement by FDA Commissioner Gottlieb on New Strategies to Modernize Clinical Trials to Advance Precision Medicine, Patient Protections and More Efficient Drug Development

Modernizing clinical trials is an agency wide priority. As more diseases are being redefined based on genomic subtype, researchers have more novel targets and more opportunities to precisely modulate or even repair the basic biological drivers of illness. Precision guided medicines can demonstrate strong efficacy signals in early clinical trials, …

Read More »

Large Trial Validates Detection of AR-V7 Biomarker Using Epic Sciences’ Platform to Predict Treatment Outcomes for Prostate Cancer Patients

SAN DIEGO, March 13, 2019 /PRNewswire/ — Epic Sciences, Inc. (Epic) today announced the publication of results from a multicenter prospective trial validating the biomarker AR-V7 (androgen receptor splice variant-7) as a predictor of resistance to anti-androgen therapy in men with metastatic castration-resistant prostate cancer (mCRPC). Data from the PROPHECY …

Read More »

HitGen and SPARC Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration

CHENGDU, China & MUMBAI, India–(BUSINESS WIRE)–HitGen Ltd. and Sun Pharma Advanced Research Company Ltd. (SPARC) (Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872) today announced a research collaboration to identify novel small molecule leads for targets of interest. Under this collaboration, HitGen will apply its advanced technology platform, based …

Read More »

RDx BioScience Genetic Risk Testing Identifies Harmful Mutation in BRCA1 or BRCA2 Human Genes Indicating Higher Likelihood of Breast Cancer

KENILWORTH, N.J.–(BUSINESS WIRE)–RDx BioScience (RDx) calls for increased use of genetic testing to identify mutations in BRCA1 and BRCA2, the genes discovered in the 1990s to be strongly associated with a high risk of breast cancer. RDX, a single source for care quality, risk evaluation and opioid expertise powered by a fast, full-service laboratory, raises awareness …

Read More »

Alexion Collaborates with Caelum Biosciences to Develop Targeted Therapy for Light Chain Amyloidosis

BOSTON & NEW YORK–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and Caelum Biosciences today announced a collaboration to develop CAEL-101 for light chain (AL) amyloidosis. CAEL-101 is a first-in-class amyloid fibril targeted therapy designed to improve organ function by reducing or eliminating amyloid deposits in patients with AL amyloidosis. AL amyloidosis is …

Read More »

ASCO and Tempus Collaborate to Help Research Sites Identify Potential Participants for the Targeted Agent and Profiling Utilization (TAPUR) Study

ALEXANDRIA, Va. and CHICAGO, Jan. 10, 2019 (GLOBE NEWSWIRE) — The American Society of Clinical Oncology, Inc. (ASCO) and Tempus announced today an agreement to support research sites participating in ASCO’s Targeted Agent and Profiling Utilization (TAPUR™) Study. The TAPUR Study is a prospective, non-randomized clinical trial that aims to …

Read More »